Dr. Deepam Pushpam

Name: Dr. Deepam Pushpam

Qualification: MD (Internal Medicine), DM (Medical Oncology)

Designation: Assistant Professor, Department of Medical Oncology.

Address: Room No. 245, Department of Medical Oncology 2nd Floor, Dr B.R.A-I.R.C.H, AIIMS , Ansari Nagar, New Delhi 110029.

Contact info: Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Academic career: Dr. Deepam Pushpam graduated from the Guwahati Medical College, Guwahati University and received his MD degree in Internal Medicine from AIIMS, Delhi. He did his senior resident ship in Medical oncology at the Dr. B. R. A- IRCH, AIIMS, New Delhi and completed his DM degree in Medical Oncology from AIIIMS. He was recruited as a faculty in Medical Oncology at the Dr. B R A –IRCH, AIIMS, New Delhi in 2018.

Area of Expertise: Dr. Deepam Pushpam is a member of the multidisciplinary teams at Dr. B.R.A-IRCH taking care of   pediatric solid cancer, soft tissue sarcoma, melanoma, pediatric and adult hematological malignancies and hematopoietic stem cell transplant. He routinely takes care of these patients in the OPD and wards. He has keen interest in hematopoietic stem cell transplant for congenital disorders in children, cord blood transplant, allogeneic hematopoietic stem cell transplant and haploidentical stem cell transplant. He also actively participates in clinical services for lung cancer.

Research interest: Acute lymphoblastic leukemia, chronic myeloid leukemia, rare pediatric tumors, and soft tissue sarcoma.

Awards:

1. Geeta Mittal Award for Best Research in Oncology AIIMS, Delhi 2018.
2. Best Thesis in Oncology ICON 2018

Membership of Professional bodies:

1.            Member: European Society for Medical Oncology, (ESMO).

2.            Member: Indian Society of Medical and Paediatric Oncology,(ISMPO)

3.            Member: Paediatric Hemato-Oncology chapter of Inadian Academy of Paediatrics (PHO-IAP)

Selected publications:

1. Pushpam, D., Bakhshi, S. Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective. DARU J Pharm Sci (2020). doi.org/10.1007/s40199-019-00321-z
2. Pushpam D, Bakhshi S. Paediatric chronic myeloid leukaemia: Is it really a different disease?Indian J Med Res. 2019 May;149(5):600-609. doi: 10.4103/ijmr.IJMR_331_19. Review.
3. Pushpam D, Rajput N, Chopra A, Vishnubhatla S, Kumari M, Kumar R, Bakhshi S.Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2019 Apr;36(3):138-150. doi: 10.1080/08880018.2019.1594469. Epub 2019 May 3.
4. Pushpam D, Chopra A, Sreenivas V, Kumar R, Bakhshi S.Absolute Lymphocyte Count at the End of Induction as a Surrogate Marker for Minimal Residual Disease in T-cell Acute Lymphoblastic Leukemia. Pushpam D, Chopra A, Sreenivas V, Kumar R, Bakhshi S. Indian Pediatr. 2019 May 15;56(5):381-383.
5. Ganguly S, Pushpam D, Mian A, Chopra A, Gupta R, Bakhshi S. Real-world Experience of Imatinib in Pediatric Chronic Phase Chronic Myeloid Leukemia: A Single-center Experience From India. Clin Lymphoma Myeloma Leuk. 2020 Mar 6. pii: S2152-2650(20)30112-9. doi: 10.1016/j.clml.2020.02.015.
6. Kancharla H, Gundu N, Pathak N, Vandidassane I, Khurana S, Pushpam D, Jain D, Kumar S, Pathy S, Mohan A, Malik PS.Cytotoxic chemotherapy in advanced non-small cell lung cancer with poor performance status: A retrospective analysis from routine clinical practice. Curr Probl Cancer. 2020 Jan 20:100550. doi: 10.1016/j.currproblcancer.2020.100550.Review.